Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring
Abstract Deferasirox (DFX) is the newest among three different chelators available to treat iron overload in iron-loading anaemias, firstly released as Dispersible Tablets (DT) and more recently replaced by Film-Coated Tablets (FCT). In this retrospective observational study, pharmacokinetics, pharm...
Guardado en:
Autores principales: | Andrea Piolatto, Paola Berchialla, Sarah Allegra, Silvia De Francia, Giovanni Battista Ferrero, Antonio Piga, Filomena Longo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5ec962bf5733487bb7ac0972af87b973 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
por: Ena J, et al.
Publicado: (2012) -
Deferasirox y Tubulopatía Proximal Compleja. Presentación de dos casos clínicos
por: Niño Taravilla,Carmen, et al.
Publicado: (2021) -
Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. A Case Series and Literature Review
por: Alqanatish J, et al.
Publicado: (2021) -
Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
por: Etienne Paubelle, et al.
Publicado: (2013) -
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
por: Sujian Xia, et al.
Publicado: (2013)